Q3 2025 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Glioblastoma (GBM) remains the most aggressive and treatment-resistant primary brain tumor, with median overall survival rarely exceeding 15–20 months despite advances in surgery, imaging, and systemic therapy. The key barriers are persistent: incomplete resection, limited drug penetration across the blood–brain barrier (BBB), and a microenvironment that suppresses immune activity while promoting recurrence. In [...]
Protokoll Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Halvårsrapport 2025 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
This document has been prepared by Double Bond Pharmaceutical for the purpose of summarising current scientific literature and providing a short assessment of the challenges and therapeutic opportunities in glioblastoma treatment. 13th August 2025. Glioblastomas' significant heterogeneity complicates diagnosis in an era of increasing reliance on genotyping, as traditional biopsies may provide an [...]
Förslag Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Kallelse Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Anmälan Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Årsstämma 2025 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Disclaimer Viktig information På grund av legala restriktioner är informationen på den här delen av webbplatsen inte avsedd eller tillgänglig för vissa personer. Vi ber dig därför att ta del av följande information och lämna följande bekräftelse varje gång du önskar tillgång till här delen av webbplatsen. Vänligen notera att villkoren nedan kan [...]
